Publications

CaNIOS’ projects:

1. Smoking, Socioeconomic Status and Inflammation in SLE. Manuscript in progress. (1000 Faces, CaNIOS Investiga tors and Mai Nguyen, Med Student).

2. Predictors of Endothelial Damage in SLE. (Dr. Joyce Rauch, in collaboration with Dr.Paul Fortin, Université Laval; Dr. Ellie Aghdassi, University of Toronto; Dr, Mélanie Dieudé, University of Montreal; and Dr. Eric Boilard, Université Laval).

3. Longitudinal Outcomes of Patients with Childhood-Onset SLE (Dr. Earl Silverman, with Dr. Lily Lim, CaNIOS trainee and PhD candidate)

4. Systematic Review of Quality of Prognosis Studies in SLE. (Dr. Earl Silverman, with Dr. Lily Lim, CaNIOS trainee and PhD candidate.

5. Platelet- derived Microvesicles and their Role on Disease Activity and Vascular Events in SLE (Drs. Paul R Fortin and Eric Boilard, with summer student Vincent Bissonnette).

6. Hospitalizations in SLE(Dr. Janet Pope, with trainees June Lee and Chayawee Muangchant, paper under review).

Journal Articles (Published)

2013

Bourre-Tessier J, Peschken CA, Bernatsky S, Joseph L, Clarke AE, Fortin PR, et al. Smoking is associated with cutaneous manifestations in systemic lupus erythematosus. Arthritis care & research. 2013. Epub 2013/02/13.

2012

Borowoy AM, Pope JE, Silverman E, Fortin PR, Pineau C, Smith CD, Arbillaga H, Gladman D, Urowitz M, Zummer M, Hudson M, Tucker L, Peschken C. Neuropsychiatric Lupus: The Prevalence and Autoantibody Associations Depend on the Definition: Results from the 1000 Faces of Lupus Cohort. Semin Arthritis Rheum. 2012 May 15. [Epub ahead of print] PubMed PMID: 22595642.

2011

Aghdassi E, Zhang W, St. Pierre Y, Clarke AE, Morrison S, Peeva V. Landolt-Mrticorena C, Su J, Reich   H, Scholey J, Herzenberg A, Pineau C, Pope J, Peschken C, LuNNET CaNIOS Investigators, Wither J, Fortin P. Health Care Cost and Loss of Productivity in a Canadian Population of Patients with & without Lupus Nephritis. The Journal of Rheumatology 2011;38:658-66.

Bernatsky S, Peschken C, Fortin PR, Pineau CA, Urowitz M, Gladman D, Pope J, Hudson M, Zummer M, Smith CD, Arbillaga HO, Clarke AE, Canadian Network for Improved Outcomes in Systemic Lupus Erythermatosus (CaNIOS). Medication use in Systemic Lupus.  J of Rheum 2011; 38(2): 271-274.  

Borowoy A, Peschken C, Pope J, 1000 Faces of Lupus Investigators.  Neuropsychiatric Lupus: The Prevalence and Autoantibody Associations Depend on the Definition: Results from the 1000 Faces of Lupus Cohort. J Rheumatol 2011;38(1):138-9. 

2010 

Borowoy A, Peschken C, Pope J (on behalf of 1000 Faces of Lupus Investigators). The Prevalence of CNS Lupus in Canada: Results from the1000 Faces of Lupus Cohort. J Rheumatol 2010; 37:1322. 

Mittoo S, Gelber A, Hitchon C, Silverman ED, Pope JE, Fortin PR, Pineau C, Smith CD, Arbillaga H, Gladman D, Urowitz M, Zumer M, Clarke A, Bernatsky S, Hudson M, Tucker L, Petty R, CaNIOS, Peschken CA.  Clinical and Serologic Predictors of Lupus Pleuritis.  The Journal of Rheumatology 2010; 747-755.

Lalani S, Peschken C, Pope J, Clinical Features and Prognosis of Late Onset SLE: Results from the 1000 Faces of Lupus Study. J Rheumatol. 2010 Jan;37(1):38-44. Epub 2009 Dec 15. 

Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman D, Urowitz M.B., Lou W, Fortin PR. The Protective Effect of Antimalarial Drug on Thrombovascular Events in Systemic Lupus Erythematosus. Arthritis and Rheumatism. 2010 March 62(3):863-8. 

Mittoo S, Gelber A, Hitchon C, Silverman ED, Pope JE, Fortin PR, Pineau C, Smith CD, Arbillaga H, Gladman D, Urowitz M, Zummer M, Clarke A, Bernatsky S, Hudson M, Tucker L, Petty R, Canadian Network For Improved Outcomes In Systemic Lupus Erythematosus (CaNIOS), Peschken CA. Systemic Lupus Erythematosus-Related Serositis is Associated with Ribonucleoprotein Antibody: Finding from a Multi-Ethnic, Multi- Center Canadian Cohort . J Rheumatol. 2010 Feb 37(4):747-53, 2010. 

Yip J, Aghdassi E, Su J, Lou W, Reich H, Bargman J, Scholey J, Gladman D, Urowitz MB, and Fortin PR. Serum Albumin as a Marker for Disease Activity in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology 2010 Aug 1: 37(8):1667-72. 

Cooper G, Wither J, Bernatsky S, Claudio J, Clarke A, Rioux J, CaNIOS Collaborators, Fortin PR. Occupational and Environmental Exposures and Risk of SLE: Silica, Sunlight, Solvents. Rheumatology 2010; doi: 10.1093/rheumatology/keq214. (SA) 

2009 

Aghdassi E, Morrison S, Landolt-Marticorena C, Su J, Pineau C, Gladman D, Urowitz M. B., Pope J, Peschken C, CaNIOS LuNNET & HIPP Investigators, DaCosta D, Wither J, Fortin PR. The Use of Micronutrient Supplements is not Associated with Better Quality of Life & Disease Activity in Canadian Patients with Systemic Lupus Erythematosus. Journal of Rheumatology. 2010 Jan; 37(1):87-90. Epub 2009 Dec 1. 

Neville C, Rauch J, Kassis J, Solymoss S, Joseph L, Belisle P, Fortin PR (*Neville C and Rauch J contributed equally to this research). Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort. Thrombosis and Haemostasis. 2009;101(1):100-7 PMID: 19132195 (SA). 

Peschken CA, Katz S, Silverman E, Pope J, Fortin PR, Pineau C, Smith CD, Arbillaga H, Gladman D, Urowitz M, Zummer M, Clarke A, Bernatsky S, Hudson M, CaNIOS Investigators. Lupus in Canada: The 1000 Canadian Faces of Lupus Project Baseline Description of the Cohort. (in press) (J Rheum) 

Law G, Pope J, Lalani S, Silverman E, Cooper G, Fortin PR, Zummer M, Smith CD, Petty R, Tucker L, Albert L, Huber A, Ramsey S, Arbillaga A, Chedéville G, Hudson M, CaNIOS Investigators; Peschken, C. Barriers to Healthcare in a Multiethnic Cohort of Systemic Lupus Erythematosus (SLE) patients: Patient and Physician Perceptions. (in press) (Clinical Medicine: Arthritis and Musculoskeletal Disorders). 

Colangelo K, Pope J, Peschken, C. The minimally important difference (MID) for patient reported outcomes in systemic lupus erythematosus (SLE) including the HAQ-DI, pain, fatigue and SF-36. J Rheumatol. 2009 Oct;36(10):2231-7. Epub 2009 Sep 1. 

Baker K., Pope J., Fortin PR, Silverman E., Peschken C; 1000 Faces of Lupus Investigators; CaNIOS (Canadian Network for Improved Outcomes in SLE). Work Disability in Systemic Lupus Erythematosus is Prevalent and Predicted by Socio- demographic and Disease Related Factors. Lupus. 2009 Dec;18(14):1281-8. Epub 2009 Oct 23. PMID: 19854811 [PubMed - indexed for MEDLINE] 

Yuen SY, Mok MY, Wong WS, .Silverman ED, Pope JE, Fortin PR, Smith CD, Zummer M, Hudson M, Pineau C. Clarke A, Bernatsky S, Urowitz M, Gladman D, Canadian Network For Improved Outcomes In Systemic Lupus Erythematosus (CaNIOS), Peschken CA. Systemic Lupus Erythematosus: A Comparative Study of Clinical Manifestations and Damage in Two Chinese Populations. Journal of Rheumatology. 2009 November; 36(11):2577-78. 

2008 

Bernatsky S, Joseph L, Boivin JF, Gordon C, Urowitz M, Gladman D, Fortin PR, Ginzler E, Bae SC, Barr S, Edworthy S, Isenberg D, Rahman A, Petri M, Alarcón GS, Aranow C, Dooley MA, Rajan R, Sénécal JL, Zummer M, Manzi S, Ramsey-Goldman R, Clarke AE. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis. 2008 Jan;67(1):74-9. Epub 2007 Jun 1. PMID: 17545189 [PubMed - indexed for MEDLINE] 

Cooper GC, Wither JE, McKenzie T, Claudio J, CaNIOS GenES Investigators, Fortin PR. The prevalence and accuracy of self-reported history of eleven autoimmune diseases. J Rheumatol. 2008:35(10):1-4. 

Hudson M, Bernatsky S, Taillefer S, Fortin PR, Wither J, Canadian Scleroderma Research Group (CSRG); Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS), Baron M. Patients with systemic autoimmune diseases could not distinguish comorbidities from their index disease. J Clin Epidemiol. 2008 Mar 12; [Epub ahead of print] PMID: 18342489 [PubMed - as supplied by publisher] 

Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, Leon JM, Burtt NP, Guiducci C, Parkin M, Gates C, Plenge RM, Behrens TW, Wither JE, Rioux JD, Fortin PR, Cunninghame – Graham D, Wong AK, Vyse TJ, Daly MJ, Altshuler D, Moser KL and Gaffney PK. A Genome-Wide Scan Identifies Association of Tumor Necrosis Factor Alpha Inducible Protein 3 (TNFAIP3/A20) with Systemic Lupus Erythematosus. Nat Genet. 2008; Aug 1. [Epub ahead of print] PMID: 18677312. 

Graham DS, Vyse TJ, Fortin PR, Montpetit A, Cai YC, Lim S, McKenzie T, Farewell L, Rhodes B, Chad L, Hudson TJ, Sharpe A, Terhorst C, Greenwood CM, Wither J, Rioux JD. Association of LY9 in UK and Canadian SLE families. Genes Immun. 2008 Mar;9(2):93-102. Epub 2008 Jan 24.PMID: 18216865. 

Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M, and the Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus. Steroid- Sparing Effects of Methotrexate in Systemic Lupus Erythematosus. Arthritis Rheum. 2008 Dec 15;59(12):1796-804 PMID: 19035431. 

Landolt-Marticorena C, Bonventi G, Lubovich A, Ferguson C, Unnithan T., Su J, Gladman D, Urowitz M, Fortin PR, Wither J. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in Systemic Lupus Erythematosus. Ann Rheum Dis. 2008 Sep 4. [Epub ahead of print] PMID: 18772188. 

Wither, J., Cai, Y.C., Lim, S., McKenzie, T., Claudio, J.O., Cooper, G.S., Hudson, T.J., Greenwood, C.M.T., Gladman, D., Pope, J., Pineau, C., Smith, C.D., Hanly, J., Peschken, C., Boire, G., CANIOS Investigators, and Fortin, PR. Reduced proportions of NKT cells are present in the relatives of lupus patients and are associated with autoimmunity. Arthritis Res Ther. 2008; 10(5):R108. Epub 2008 Sept. 10. PMID: 18783591. 

2007 

Bernatsky S, Ramsey-Goldman R, Boivin J-F, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Petri M, Edworthy E, Barr S, Gordon C, Bae S-C, Sibley J, Isenberg D, Rahman A, Aranow C, Dooley M-A, Steinsson K, Nived O, Sturfelt G, Alarcon G, Senecal J-L, Zummer M, Hanly J, Ensworth S, Pope J, El-Gabalawy H, McCarthy T, St. Pierre Y, Clarke A. An international cohort study of cancer in systemic lupus erythematosus (SLE). Arthritis and Rheumatism (accepted for publication) 

Bernatsky S, Ramsey-Goldman R, Isenberg D, Rahman A, Dooley MA, Sibley J, Boivin JF, Joseph L, Armitage J, Zoma A, Clarke A. Hodgkin’s lymphoma in systemic lupus erythematosus. Rheumatology (Oxford). 2007 May; 46(5): 830-2. Epub 2007 Jan 25. PMID: 17255135 

Bernatsky S, Boivin JF, Joseph L, Gordon C, Urowitz M, Gladman D, Ginzler E, Fortin P, Bae SC, Barr S, Isenberg D, Rahman A, Petri M, Alarcon G, Aranow C, Dooley MA, Rajan R, Senecal JL, Zummer M, Manzi S, Edworthy S, Ramsey-Goldman R, Clarke A. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case-cohort study. Ann Rheum Dis. 2007 Jun 1; PMID: 17545189. 

Bin J, Bernatsky S, Gordon C, Boivin JF, Ginzler E, Gladman D, Fortin PR, Urowitz M, Manzi S, Isenberg D, Rahman A, Petri M, Nived O, Sturfeldt G, Ramsey-Goldman R, Clarke AE. Lung cancer in Systemic lupus erythematosus. Lung Cancer. 2007 Jun;56(3):303-6. PMID: 17291624. 

2006 

Bernatsky SR, Cooper GS, Mill C, Ramsey-Goldman R, Clarke AE, Pineau CA. Cancer screening in partients with systemic lupus erythematosus. J Rheumatol. 2006 Jan;33(1):45-9. Epub 2005 Dec 1. PMID: 16331804 [PubMed - indexed for MEDLINE 

Bernatsky S, Clarke A, Gladman DD, Urowitz M, Fortin PR, Barr SG, Senecal JL, Zummer M, Edworthy S, Sibley J, Pope J, Ensworth S, Ramsey-Goldman R, Hanly JG. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus. 2006;15(12):835-839. 

Bernatsky S, Clarke A, Pope J, Hanly JG, Smith CD, Peschken C, Rich E, Boire G, Fortin PR. Malignancy prevalence in the first-degree relatives of persons with systemic lupus erythematous: a pilot study. Lupus. 2006;15(10):695-6. No abstract available. PMID: 17120599. 

Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006 Aug;54(8):2550-7. PMID: 16868977. 

2005 

Bernatsky S, Ramsey-Goldman R, Boivin J-F, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Petri M, Edworthy E, Barr S, Gordon C, Bae S-C, Sibley J, Isenberg D, Rahman A, Aranow C, Dooley M-A, Steinsson K, Nived O, Sturfelt G, Alarcon G, Senecal J-L, Zummer M, Hanly J, Ensworth S, Pope J, El-Gabalawy H, McCarthy T, St. Pierre Y, Clarke A. An international cohort study of cancer in systemic lupus erythematosus (SLE). Arthritis and Rheumatism 2005;52(5):1481-90. 

Bernatsky S, Boivin J-F, Joseph L, Manzi S, Ginzler E, Urowitz M, Gladman DD, Fortin PR, Gordon C, Barr S, Edworthy S, Bae S-C, Petri M, Sibley J, Isenberg D, Rahman A, Steinsson K, Aranow C, Dooley MA, Alarcón G, Hanly J, Sturfelt C, Nived O, Pope J, Ensworth S, Rajan R, El-Gabalawy H, McCarthy T, St. Pierre Y, Clarke A, Ramsey- Goldman R. Race/Ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis and Rheumatism. 2005;53(5):781-784. 

Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Petri M, Edworthy S, Barr S, Gordon C, Bae SC Sibley J, Isenberg D, Rahman A, Aranow C, Dooley MA, Steinsson K, Nived O, Sturfelt G, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, El-Gabalawy H, McCarthy T, St Pierre Y, Ramsey-Goldman R, Clarke A. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 2005 May;52(5):1481-90. PMID: 15880596 

Bernatsky S, Ramsey-Goldman R, Rajan R, Boivin J-F, Joseph L, Lachance S, Cournoyer D, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman DD, Fortin PR, Edworthy S, Barr S, Gordon C, Bae S-C, Steinsson K, Sturfelt C, St. Pierre Y, Clarke A. Non-Hodgkin’s lymphoma in systemic lupus erythematosus. Ann Rheum. Dis. 2005;64:1507-1509. 

2003 

Edworthy SM, Dobkin PL, Clarke A, et al. Group psychotherapy reduces illness intrusiveness in systemic lupus erythematosus. J Rheumatol 2003;30(5):1011-1016. 

Yen JC, Abrahamowicz M, Dobkin PL, Clarke AE, Battista RN, Fortin PR. Determinants of discordance between patients and physicians in their assessment of lupus disease activity. Journal of Rheumatology. 2003 Sep;30(9):1967-76. 

2002 

Chang E, Abrahamowicz M, Ferland D, Fortin PR. CaNIOS Investigators. Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians. Journal of Clinical Epidemiology. 2002;55(5):488-497. 

Chang ER, Abrahamowicz M, Ferland D, Fortin PR. Organ manifestations influence differently the responsiveness of two lupus disease activity measures, according to patients’ or physicians’ evaluations of recent lupus activity. J Rheumatol 2002;29(11):2350-2358. 

Dobkin PL, Da Costa D, Joseph L, Fortin PR, Edworthy S, Barr S, Ensworth S, Esdaile JM, Beaulieu A, Zummer M, Senécal JL, Goulet JR, Choquette D, Rich E, Smith D, Cividino A, Gladman D, St-Pierre Y, Clarke AE. Counterbalancing patient demands with evidence: Results from a Pan-Canadian randomized clinical trial of brief supportive- expressive group psychotherapy for women with systemic lupus erythematosus. Annals of Behavioural Medicine. 2002;24(2):88-99. 

2001 

Dobkin PL, Da Costa D, Fortin PR, Edworthy S, Barr S, Esdaile JM, Senécal J-L, Goulet J- R, Choquette D, Rich E, Beaulieu A, Cividino A, Ensworth S, Smith D, Zummer M, Gladman D, Clarke AE. Living with lupus: a prospective pan-Canadian study. J Rheumatol 2001; 28(11):2442-2448. 

Dobkin PL, Da Costa D, Fortin PR, Edworthy S, Barr S, Esdaile JM, Senecal JL, Goulet JR, Choquette D, Rich E, Beaulieu A, Cividino A, Ensworth S, Smith D, Zummer M, Gladman DD, Clarke AE. Living with lupus: A prospective pan-Canadian study. Journal of Rheumatology. 2001;28(11):2442-2448. 

1995 - 2000 

Ferland D, Fortin PR. Recruitment strategies in superiority trials in SLE: lessons from the study of methotrexate in lupus erythematosus (SMILE). Lupus 1999;8:606-611. 

Manuscripts In Press 
 
Peschken CA, Katz S, Silverman E, Pope J, Fortin PR, Pineau C, Smith CD, Arbillaga H, Gladman D, Urowitz M, Zummer M, Clarke A, Bernatsky S, Hudson M, CaNIOS Investigators.  Lupus in Canada: The 1000 Canadian Faces of Lupus Project Baseline Description of the Cohort (in press) (J Rheum)
 
Lee J, Peschken C, Muangchan C, Silverman E, Pineau C, Smith CD, Arbillaga H, Zummer M, Clarke A, Bernatsky S, Hudson M, Tucker L, Huber A, Ramsey S, Chedeville G, Hitchon C, Fortin F, Pope J. The Frequency of and Associations with Hospitalization Secondary to Lupus Flares from the 1000 Faces of Lupus Canadian Cohort. Submitted.
 
Levy DM, Peschken CA, Tucker LB, Chedeville G, Huber A, Pope JE.  Canadian Network for ImprovedOutcomes in SLE (CaNIOS) 1000 Faces Investigators) Silverman E.   The 1000 Canadian Faces of Lupus:Influence of Ethnicity on Disease in the Pediatric Cohort. Arthritis Care and Research June 2012 in press.
 
Josiane Bourré-Tessier; Christine A Peschken; Sasha Bernatsky; Lawrence Joseph; Ann E Clarke; PaulR Fortin; Carol Hitchon; Shikha Mittoo; C Douglas Smith; Michel Zummer; Janet Pope; Lori Tucker;Marie Hudson; Hector Arbillaga; John Esdaile; Simon Carette; Earl Silverman ; Gaelle Chédeville;Adam M Huber; Patrick Belisle; CaNIOS 1000 Canadian Faces of Lupus investigators and Christian APineau. Smoking is Associated with Cutaneous Manifestations in Systemic Lupus Erythematosus. Manuscriptsubmitted.
 
Zhang W, Aghdassi E, Reich HN., Su J, Lou W, Landolt-Marticorena C, Gladman D, Urowitz M, Scholey J, Fortin PR. Glomerular Filtration Rate Predicts Arterial Events in Women with Systemic Lupus Erythematosus. Rheumatology (In Press – September 2010)(RHE-10-0713.R1) 
 
Burdarf ML, Goyette P, GenES Investigators, Boucher G, Lian J, Graham RR, Claudio JO, Hudson T, Barr SG, Boire G, Clarke AE, Gladman D, Hanly J, Peschken C, Pope JE, Rich E, Smith CD, Zummer M, Fortin PR, Wither J, Rioux JD. A targeted association study in Systemic Lupus Erythematosus (SLE) identifies novel risk alleles, and replicates known susceptibility alleles. Genes and Immunity (In Press - April 2010) 
 
Bernatsky S, Peschken C, Fortin PR, Urowitz MB, Gladman DD, Pope E, Hudson M, Zummer M, Smith D, Arbillaga H, Clarke A. Medication Use in Systemic Lupus. Journal of Rhematology (In Press - 2010-0414.R1) (June 2010) 
 
Cooper G, Wither J, Bernatsky S, Claudio J, Clarke A, Rioux J, CaNIOS Collaborators, Fortin PR. Occupational and Environmental Exposures and Risk of SLE: Silica, Sunlight, Solvents. Rheumatology 2010; doi: 10.1093/rheumatology/keq214. 
 
Aghdassi E, Ma D WL, Morrison S, Hillyer L M, Clarke S, Gladman DD, Urowitz MB, Fortin PR. Alteration in Circulating Fatty Acid Composition in Patients with Systemic Lupus Erythematosus: A Pilot Study. Journal of Parenteral and Enteral Nutrition (In Press – Manuscript ID JPEN-2010-03-051)(August 2010) 
 
Books 
 
1. Lupus: the disease with a thousand faces. Your Personal Health Series. Eds. Jean-Luc Senécal and Sasha Bernatsky. Key Porter Books. 2004. (Coll). 
 
Abstracts (Published) 
 
Borowoy A, Peschken C, Pope J on behalf of 1000 Faces of Lupus Investigators. CNS Lupus: The Prevalence and Antibodies Depend on the Definition. Results from the 1000 Faces of Lupus Cohort. ArthritisRheum 2010;62:S775.
2010 
 
111. Aghdassi E, Ma D.W., Morrison S, Hillyer L.M., Gladman D.D., Urowitz M.B., Fortin PR. Alteration in Circulating Fatty Acid Composition in Patients with Systemic Lupus Erythematosus (SLE). Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
110. Jeyalingam T., Su J., Brown P.E., Peschken C.A., Pope J.E., CaNIOS Investigators and Fortin PR. Distance to Lupus Centre and Health Care Barriers in Systemic Lupus Erythematosus. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
109. Dieude M, Correa J, Neville C, Pineau C, Levine J, Subang R, Landolt-Marticorena C, Su J, Kassis J, Solymoss S, Fortin PR and Rauch J. Autoantibodies to Heat Shock Protein 60 Are Associated with Arterial Vascular Events in Patients with Anti-Phospholipid Antibodies. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
108. Yip J., Aghdassi E., Su J., Lou W., Reich H., Bargman J., Scholey J., Gladman D.D., Urowitz M.B., Fortin PR. Serum Albumin as a Marker for Disease Activity in Patients with Systemic Lupus Erythematosus (SLE). Lupus, June 2010; vol. 19, 1 suppl: pp. 1- 185. 
 
107. Zhang W, Aghdassi E, St-Pierre Y, Clarke AE., Landolt-Marticorena C., Morrison S, Su J., Reich H., Scholey J., Herzenberg A., Pineau C., Pope J., Peschken C., CaNIOS Investigators, Wither J. and Fortin PR. Health Care Cost in a Canadian Population of Patients With & Without Lupus Nephritis. Accepted for poster presentation at the 2010 Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
106. Aghdassi E, Cheung AM, Peeva V, Morrison S, Cymet A, Su J, Neville C, Hewitt S, Morin S, McDonald-Blumer H, CaNIOS HIPP Investigators, Pineau C, Pope J, Da Costa D, Fortin PR. Low Bone Mass in Female Patients with Systemic Lupus Erythematosus (SLE): A Canadian Study. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
105. Morrison S, Aghdassi E, Peeva V, Su J, Landolt-Marticorena C, Gladman DD, Urowitz MB, Pineau C, Pope J, Peschken C, CaNIOS LuNNET Investigators, Wither J and Fortin PR. Perceived Stress in Female Patients with Systemic Lupus Erythematosus (SLE). Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
104. Jeyalingam T., Aghdassi E., Su J., Clarke AE., Cooper GS., Rioux JD., Wither J., CaNIOS GENES-Investigators, Fortin PR. Quality of Life of Patients With Systemic Lupus Erythematosus (SLE) and Their Family Members. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
103. Jeyalingam T., Su J, Brown P, Peschken C, Pope J, CaNIOS 1000 Faces Investigators, Fortin PR. Distance to Lupus Centre and Health Care Barriers in Systemic Lupus Erythematosus. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
102. Peeva V, Aghdassi E, Su J, Gladman DD, Urowitz MB., Landolt-Marticorena C, Yeo E, Fortin PR. Clinical Characteristics and Quality of Life of Patients with Primary and Secondary Antiphospholipid Syndrome. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
101. Peeva V, Aghdassi E, Su J, Morrison S, Cymet A, Harvey P, Neville C, Hewitt S, Pineau C, Pope J, Da Costa D, Fortin PR. Cardiovascular Risk Factors in Patients with Systemic Lupus Erythematosus without Past History of Cardiovascular Event. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
100. Zhang W, Aghdassi E, Reich HM, Su J, Lou W, Landolt-Marticorena C, Gladman DD, Urowitz MB, Scholey JW and Fortin PR. Poor Renal Function In Patients with Systemic Lupus Erythematosus (SLE) Predicts Cardiovascular Events. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
99. Bernatsky S, Peschken C, Urowitz MB, Gladman DD, Clarke A, Pope J, Fortin PR, Pineau C, Zummer M, Smith CD, Arbillaga H, Hudson M, CaNIOS 1000 Canadian Faces of Lupus. Medication Use in Systemic Lupus Erythematosus. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
98. Peeva V, Su J, Aghdassi E, Gladman DD, Urowitz MB, Landolt-Marticorena C, Yeo EL, Fortin PR. Clinical Characteristics and Quality of Life of Patients with Primary and Secondary Antiphospholipid Syndrome. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185.  
 
97. Neville C, Rauch J, Kassis J, Solymoss S, Joseph L, Belisle P, Fortin PR. Antiphospholipid Antibodies Predict Future Arterial Events: Results from the Montreal Antiphospholipid Study (MAPS) at Eleven Years of Follow Up. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
96. Peeva V, Aghdassi E, Morrison S, Cymet A, Su J, Harvey P, Neville C, Hewitt S, Pineau C, Pope J, Dacosta D, Fortin PR. Framingham Scores and Individual Cardiovascular Disease (CVD) Risk Factors in Patients with Systemic Lupus Erythematosus (SLE) without Past History of Cardiovascular Events. Lupus, June 2010; vol. 19, 1 suppl: pp. 1- 185. 
 
95. Aghdassi E, Cheung A.M., Peeva V, Morrison S, Cymet A, Su J, Neville C, Hewitt S, Morin S, McDonald-Blumer H, CaNIOS Investigators, Pineau C, Pope J, Da Costa D, Fortin PR. Low Bone Mass in Female Patients with Systemic Lupus Erythematosus (SLE): A Canadian Study. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
94. Morrison S, Aghdassi E, Peeva V, Su J, Landolt-Marticorena C, Gladman DD, Urowitz MB, Pineau C, Pope J, Peschken C, Wither J, Fortin PR. Perceived Stress in Female Patients with Systemic Lupus Erythematosus (SLE). Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
93. Landolt-Marticorena C, Morrison S, Reich H, Aghadassi E, Hertzenberg A, Scholey J, Gladman D, Urowitz MB, Fortin PR, Wither JE. Clinical Utility of Changes in Cyto/Chemokines as Markers of Disease Activity in Systemic Lupus Erythematosus. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
92. Landolt-Marticorena C, Reich H, Morrison S, Aghadassi E, Pineau C, Scholey J, Gladman D, Urowitz M, Hertzenberg A, Fortin PR, Wither JE. Urinary cyto/chemokines correlates with renal histopathology in Systemic Lupus Erythematosus. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
91. Peschken CA, Silverman E, Pope JE, Fortin PR, Pineau CA, Tucker LB, Zummer M, Hudson M, Urowitz M, Gladman DD, Clarke A, Bernatsky S, Chedeville G, Huber A, Ramsey SE, Smith CD, Arbillaga H, CaNIOS 1000 Faces Investigators. Lupus in Asian Canadians: The 1000 Canadian Faces of Lupus Study. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
90. Aghdassi E, Zhang W, St-Pierre Y, Clarke AE, Landolt-Marticorena C, Morrison S, Su J, Reich H, Scholey J, Herzenberg A, Pineau C, Pope J, CaNIOS Investigators, Wither J, Fortin PR. Health Care Cost in a Canadian Population of Patients with and without Lupus Nephritis. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
89. Florica B., Su J., Aghdassi E., Gladman DD., Urowitz MB., Fortin PR.. Peripheral Neuropathy in Patients with Systemic Lupus Erythematosus (SLE). Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
88. Huang D., Aghdassi E., Su J, Fortin PR. The Prevalence of Liver Abnormalities in Patients with Systemic Lupus Erythematosus. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
 
86. Borowoy A, Peschken C, Pope J on behalf of 1000 Faces of Lupus Investigators. CNS Lupus: The Prevalence and Antibodies Depend on the Definition. Results from the 1000 Faces of Lupus Cohort. Submitted for presentation at the American College of Rheumatology Annual Scientific Meeting, Atlanta, GA, Nov. 7-11, 2010. 
 
85. Lee J, Pope J, Peschken C on behalf of 1000 Faces of Lupus. Hospitalization in Systemic Lupus Erythematosus (SLE): Incidence and Predictors of Hospitalization in Systemic Lupus Erythematosus (SLE): Results from a Large Contemporary Multi-Ethnic Cohort. Submitted for presentation at the American College of Rheumatology Annual Scientific Meeting, Atlanta, GA, Nov. 7-11, 2010. 
 
2009
 
84. Akhavan P., Neville C., Su J., Kassis J., Solymoss S., Pineau C., Peschken C., Pope J., Boire G., Rauch J., Fortin PR. Vascular Events in Systemic Lupus Erythematosus (SLE): Evaluation of Thrombophilic Factors in a Multicentre Inception Cohort (ThromboFIL). Journal of Rheumatology. 2009; 36:11; 2604-5. . 
 
83. Aghdassi E., Morrison S., Landolt-Marticorena C., Su J., Pineau C., Pope J., Peschken C., Gladman D., Urowitz M., CaNIOS LuNNET Investigators, Wither J., Fortin PR. Quality of life in lupus patients with and without renal involvement. Journal of Rheumatology. 2009; 36:11; 2563. 
 
82. Aghdassi E., Su J., Claudio J., Morrison S., Cymet A., Neville C., CaNIOS Investigators, DaCosta D., Fortin PR. The Use of Micronutrient Supplements among Patients with Systemic Lupus Erythematosus. Journal of Rheumatology. 2009; 36:11; 2583-4.. 
 
81. Dhanhani A., Harvey P., Su J., Pineau C., Cymet A., DaCosta D., Fortin PR. The Excess Of Endothelial Dysfunction in SLE is not Explained by Framingham Cardiac Risk Factors. Journal of Rheumatology. 2009; 36:11; 2588.. 
 
80. Adams K., Landolt-Marticorena C., Unnithan T., Gladman D., Urowitz M., Fortin PR, Wither J. Circulating levels of sVCAM, IP-10 and MCP-1 correlate with changes in disease activity in Systemic Lupus Erythematosus. Journal of Rheumatology. 2009; 36:11; 2559. 
 
79. Kim J., Aghadassi E., Gladman D., Urowitz M., Fortin PR, and Wither J. Evidence for altered activation of newly-emergent bone marrow-derived B cells in Systemic Lupus Erythematosus (SLE). Accepted for poster presentation at the Canadian Rheumatology Association 64th Annual Meeting and Scientific Program, Kananaskis, Alberta, February 18 -21, 2009. 
 
78. Colangelo K, Pope J, Peschken C, and Members of 1000 Faces of Lupus. The minimally important difference for patient reported outcomes in SLE including pain, fatigue and SF36. Accepted for poster presentation at the Canadian Rheumatology Association 64th Annual Meeting and Scientific Program, Kananaskis, Alberta, February 18 -21, 2009. 
 
77. Baker K, Pope J, Silverman E, Cooper G, Fortin PR, Zummer M, Smith CD, Petty, R. Tucker L, Albert L, Huber A, Ramsey S, Arbillaga H, Chedéville G, Hudson, M, CaNIOS Investigators; Peschken C.. Work Disability in Systemic Lupus Erythematosus is Prevalent and Predicted by Socio-demographic and Disease Related Factors: Results from a Multi- Ethnic Cohort. Journal of Rheumatology. 2009; 36:11; 2559.. 
 
76. Yuen SY, Mok MY, Wong WS , Pope J, Silverman E, Tucker L, Smith CD, Bernatsky S, Pineau C, Zummer M, Chedeville G, Urowitz M , Gladman D, Clarke A, Fortin PR, Peschken C. Systemic Lupus Erythematosus (SLE): A Comparative Study of Clinical Manifestations and Damage in Two Chinese Populations. Journal of Rheumatology. 2009; 36:11; 2559. . 
 
75. Reich H, Landolt-Marticorena C, Boutros P C, Nasr S, Thomas D, Wither J, Yang S, Su J, Aghdassi E, Gladman D, Urowitz MB, Fortin PR, Scholey JW and Herzenberg AM. Tissue markers of injury in kidney biopsies of patients with lupus nephritis. (Submitted to the American Society of Nephrology, June 2009). 
 
74. Zhang W, Aghdassi E, Reich H, Scholey J, Su J, Fortin PR. Baseline eGFR is Predictive of Cardiovascular Diseases in Patients with Systemic Lupus Erythmatosus (SLE). Arthritis and Rheumatism. 2009;60(9suppl):1930. 
 
73. Neville C, Rauch J, Kassis J, Solymoss S, Joseph L, Belisle P, Fortin PR. Antiphospholipid Antibodies Predict Future Arterial But Not Venous Events at 11 Years of Follow-up. Arthritis and Rheumatism. 2009;60(9suppl):1214. 
 
72. Landolt-Marticorena C., Reich H., Morrison S., Aghdassi E., Pineau C.A., Scholey J., Gladman D., Urowitz M.B., Herzenberg A., Fortin PR and Wither J. Urine Cyto/Chemokines Correlate with Renal Histopathology in Systemic Lupus Erythematosus. Arthritis and Rheumatism. 2009;60(9suppl):564. 
 
71. Cooper G, Wither J, Bernatsky S, Claudio J, Clarke A, Rioux J, Paterson A, Fortin PR. New Directions for Environmental Research: Results from the Genetic and Environmental Factors in Systemic Lupus Erythematosus (GenES) Study. Arthritis and Rheumatism. 2009;60(9suppl):48. 
 
70. Aghdassi E, Zhang W, St-Pierre Y, Clarke A, Landolt C, Morrison S, Su J, Reich H, Herzenberg A, Scholey J, Pineau C, Pope J, Peschken C.A., Wither J, Fortin PR. Health Care Resource Utilization & Loss of Productivity in a Canadian Population of Patients with & without Lupus Nephritis. Arthritis and Rheumatism. 2009;60(9suppl):705. 
 
69. Bernatsky S., Peschken C, Fortin PR, Gladman D, Pope J, Clarke A, CaNIOS. Medication Use in Systemic Lupus (SLE). Arthritis and Rheumatism. 2009;60(9suppl):939. 
 
68. Landolt-Marticorena C, Morrison S., Reich H, Aghdassi E, Herzenberg A, Scholey J, Gladman D, Urowitz M, Fortin PR and Wither J. Clinical Utility of Changes in Cyto/Chemokines as Markers of Disease Activity in Systemic Lupus Erythematosus. Arthritis and Rheumatism. 2009;60(9suppl):922. 
 
67. Peschken CA, Pope J, Silverman E, Fortin PR, Pineau C, Zummer M, Urowitz M, Gladman D, Hudson M, Tucker L, Chedeville G, Huber A, Bernatsky S, Clarke A, Smith CD, Arbillaga H, Ramsey SE, and CaNIOS Investigators. Lupus in Asian Canadians: The 1000 Canadian Faces of Lupus Study. Lupus, June 2010; vol. 19, 1 suppl: pp. 1-185. 
 
66. Chang NH, Kim J, Aghdassi E, Urowitz MB, Gladman D, Fortin PR, Wither J. Increased Proximal B Cell Receptor Signaling in the Naïve B Cell Population of SLE Patients. Arthritis and Rheumatism. 2009;60(9suppl):112. 
 
2008 
 
61. Carolina Landolt-Marticorena, Alla Lubovich, Gabriel Bonventi, Thulasi Unnithan, Dafna Gladman, Murray Urowitz, Paul R. Fortin, and Joan E. Wither. Longitudinal expression of interferon responsive elements in SLE patients does not correlate with disease activity. Oral Presentation, CRA Annual Meeting. . March 5-8, 2008 in Mont Tremblant, Quebec 
 
60. Carolina Landolt-Marticorena, Gabriel Bonventi, Yongchun Cai, Thulasi Unnithan, Dafna Gladman, Murray Urowitz, Paul R. Fortin, and Joan. E. Wither. Elevated BAFF levels correlate with altered B cell phenotypes in patients with SLE. Oral Presentation, CRA Annual Meeting. . March 5-8, 2008 in Mont Tremblant, Quebec. 
 
59. Law G, Lalani S, Pope J, et al. The relationship between healthcare access and disease activity and damage in a multiethnic cohort of systemic lupus erythematosus (SLE) patients: The 1000 Canadian faces of lupus study. 2008. J Rheum 35(6):1195. 
 
58. Law G, Lalani S, Pope J, et al. The relationship between healthcare access and disease activity and damage in a multiethnic cohort of systemic lupus erythematosus (SLE) patients: The 1000 Canadian Faces of lupus study: 2008. Arthritis and Rheumatism 58 (9): S881 
 
57. Lian J, Goyette P, Graham R, GenES Investigators, Wither J, Fortin PR, Rioux J. A targeted association study in Systemic Lupus Erythematosus (SLE) identifies novel risk alleles, and replicates known susceptibility alleles. 1st Annual Canadian Human Genetics Conference in St-Sauveur, Quebec, 2008. 
 
56. Mittoo S, Gelber A,, Hitchon CA, Silverman E, Pope JE, CaNIOS Investigators, Peschken C. Predictors and Functional Impact of Lupus Lung Disease. Submitted to the American College of Rheumatology Annual Scientific Meeting, San Francisco, Oct 24-29, 2008. 
 
55. Akhavan PS, Neville C, Su J, Kassis J, Solymoss S, Pineau C, Peschken C, Pope J, Boire G, Rauch J, Fortin PR. Vascular events in systemic lupus erythematosus (SLE): evaluation of thrombophilic factors in a multicentre inception cohort (ThromboFIL). Accepted for poster presentation at the American College of Rheumatology Annual Scientific Meeting, San Francisco, Oct 24-29, 2008. 
 
54. Al Dhanhani AM, Cymet A, Harvey P, Da Costa D, Fortin PR. FMD measurement among lupus patients. Accepted for poster presentation at the American College of Rheumatology Annual Scientific Meeting, San Francisco, Oct 24-29, 2008. 
 
53. HN Reich, SC Fan, J Su, JM Bargman, J Wither, DD Gladman, MB Urowitz, AM Herzenberg, JW Scholey, DC Cattran and PR Fortin. Important Predictors of CKD in an Inception Cohort of Patients with Lupus. Oral Presentation at the American Society of Nephrology. Nov. 2008, Philadelphia, PA. 
 
2007 
 
52. Katz S, Pope J, Fortin PR, Silverman E, Chedeville G, Peschken C. 1000 Canadian faces of lupus: A look a the first year. Journal of Rheumatology, 2007;34(7) 1597. 
 
51. Wither J, Cai Y, Lim S, McKenzie T, Su J, Claudio JO, CaNIOS GenES Investigators, Cooper, G, Hudson T, Greenwood CMT, Fritzler M, Fortin PR. Increased Frequency of Autoantibodies in the Family Members of Lupus Patients and Association with a Reduced Proportion of NKT cells. Journal of Rheumatology, 2007;34(7) 1621. 
 
50. Landolt-Morticorena C, Ferguson C, Unnithan T, Gladman D, Urowitz M, Fortin PR, Wither J. Sustained T cell activation promotes disease activity in lupus. Journal of Rheumatology, 2007;34(7) 1596. 
 
49. Fortin PR, Cai Y, Lim S, McKenzie, T, Su, J. Claudio, JO, CaNIOS GenES Investigators, Cooper GS, Hudson TJ, Greenwood, CMT, Wither, JE. Reduced proportions of NKT cells in the relative of lupus patients and association with ANA. 8th International Congress on SLE May 23-27, Shanghai, China. 
 
48 Kassis J. Neville C, Rauch J, Solymoss S, Joseph L, Belisle P, Fortin PR. Factors predictors of vascular events with antiphospholipids antibodies. The American Society of Hematology, December 2007. 
 
47. Landolt-Marticorena C, Bonventi G , Cai Y, Unnithan T, Gladman D, Urowitz M, Fortin PR, and Wither JE. Elevated BAFF Levels Correlate with Altered B Cell Phenotypes in Patients with Systemic Lupus Erythematosus. Arthritis & Rheumatism 2007; (9suppl): F105. 
 
46. Cooper GS, Wither J, McKenzie T, Claudio JO, Hudson TJ, Greenwood CMT, Urowitz M, Pope J, Bernatsky S, Smith CD, Hanly JG, Hitchon C, Boire G, CaNIOS Investigators, Fortin PR. The Accuracy of Self-Reported History of Eleven Autoimmune Diseases. Arthritis & Rheumatism 2007; (9suppl): S804 
 
45. Tian YS, Shariati Z, Bobba R, Gladman D, Urowitz M, Fortin PR. Anticardiolipin Antibodies are Associated with Higher Risk of Thrombosis in Systemic Lupus Erythematosus: A Descriptive Study. Arthritis & Rheumatism 2007; (9suppl): S1924 
 
44. Tucker LB, Uribe A, Petty R., Silverman E. Chedeville G., Huber AM, Peschken C, 1000 Canadian Faces of SLE Investigators. Pediatric Systemic Lupus Erythematosus (SLE) in Canada: 1000 Canadian Faces of SLE Arthritis & Rheumatism 2007; (9suppl): S881 
 
43. Peschken CA, Pope J, Silverman E, Cooper GS, The 1000 Canadian Faces of Lupus Investigators. Ethnic Differences in Patient Perceptions of Systemic Lupus Erythematosus (SLE) Disease Activity in a Multiethnic Cohort: The 1000 Canadian Faces of Lupus Study Arthritis & Rheumatism 2007; (9suppl): S1110 
 
42. Peschken CA, Pope J, Silverman E, Cooper GS, Katz S, The 1000 Canadian Faces of Lupus Investigators. The 1000 Canadian Faces of Lupus: A look at the First Year Arthritis & Rheumatism 2007; (9suppl): S2160 
 
2006 
 
41. Kelly E, McKenzie T, Chang N, Lim S, Harrison H, Hudson T, Cooper G, Greenwood C, Fortin PR, Wither J. Evidence for abnormal B and T cell activation in lupus patients but not their parents. Canadian Rheumatology Association. Acapulco, February 2006. (won best student presentation). 
 
40. Karp I, Abrahamowicz M, Fortin PR, Pilote L, Pineau C, Neville C, Esdaile J. Recent Corticosteroid Use and Recent Disease Activity: Are They Independent Determinants of Coronary Heart Disease Risk Factors in Systemic Lupus Erythematosus? Canadian Rheumatology Association. Acapulco, February 2006. 
 
39. Bernatsky S, Clarke AE, Ramsey-Goldman R, Boivin JF, Joseph L, Gladman D, Urowitz M, Fortin PR, Ginzler E, Manzi S, Gordon C, Bae SC, Barr SG, Edworthy S, Petri M, Isenberg D, Rahman A, Aranow C, Dooley MA, Rajan R, Senecal JL, Zummer M. Lung cancer in systemic lupus erythematosus (SLE). 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, Nov 10-15, 2006 Arthritis And Rheumatism 54 (9): S280-S281 Suppl. S Sep 2006. 
 
38. Bernatsky S, Clarke AE, Gladman D, Urowitz M, Fortin PR, Barr SG, Senecal JL, Zummer M, Edworthy S, Pope J, Ramsey-Goldman R, Hanly JG. Neuropsychiatric events in SLE: Mortality related to cerebrovascular disease. 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, Nov 10-15, 2006 Arthritis And Rheumatism 54 (9): S281-S281 Suppl. S Sep 2006 
 
37. Wither JE, Chad L, Montpetit A, Montpetit A, Lim S, McKenzie T, Cooper S, Greenwood CMT, Fortin PR, Hudson TJ. Genetic Association between LY9, a member of the SLAM family, and systemic lupus erythematosus. 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of- Rheumatology-Health-Professionals, Nov 10-15, 2006 Arthritis And Rheumatism 54 (9): S290-S291 Suppl. S Sep 2006 
 
36. Wither JE, Cai YC, Lim S, McKenzie T, Su JD, Claudio JO, Cooper GS, Hudson TJ, Greenwood CMT, Fritzler M, Fortin PR. Increased frequency of autoantibodies in the family members of lupus patients and association with a reduced proportion of NKT cells. 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-Of-Rheumatology-Health-Professionals, Nov 10-15, 2006 Arthritis And Rheumatism 54 (9): S291-S291 Suppl. S Sep 2006 
 
35. Bernatsky S, Clarke AE, Ramsey-Goldman R, Boivin JF, Joseph L, Urowitz M, Gladman D, Fortin PR, Petri M, Girtzler E, Manzi S, Gordon C, Bae SC, Barr SG, Isenberg D, Rahman A, Aranow C, Dooley MA, Senecal JL, Zummer M. Cancer Risk in SLE: No strong evidence of an association with immunosuppressive drugs. 70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, Nov 10-15, 2006 Arthritis And Rheumatism 54 (9): S549-S550 Suppl. S Sep 2006 
 
34. Fortin PR, Abrahamowicz M, Cymet A, Neville C, Harvey P, Su J, Pineau c, Clarke AE, Bernatsky SR, Urowitz M, Gladman D, Abbey, Holloway T, Huynh T, Da Costa D. The Health Improvement and Prevention Program (HIPP) in systemic Lupus Erythematosus (SLE) shows preliminary benefits in reducing the estimate 8-year-risk of cardiovascular disease. Arthritis & Rheumatism 2006;54 (9 suppl) S791. 
 
2005 
 
33. Tisseverasinghe A, Fortin PR, Greenwood C, Lim S, Su J. Association between serum total cholesterol and renal outcome in systemic lupus erythematosus. Canadian Rheumatology Association Annual Meeting, March 2-5, 2005, Mont Tremblant, Quebec. 
 
32. Panopalis, P, Petri M, Manzi S, Isenberg DA, Gordon C, Senecal J-L, Penrod JR, Joseph L, St. Pierre Y, Pineau C, Fortin PR, Sutcliffe N, Goulet J-R, Choquette D, Grodzicky T, Esdaile JM, Clarke AE. American patients experience greater productivity loss despite an increase use of health care resources. Arthritis & Rheumatism 2005;52 (9 suppl) S401 
 
31. Hanly J, Urowitz M for the Systemic Lupus International Collaborating Clinics (SLICC). Neuropsychiatric events at diagnosis of systemic lupus erythematosus. Arthritis & Rheumatism 2005;52 (9 suppl) S379. 
 
30. Hanly J, Urowitz M for the Systemic Lupus International Collaborating Clinics (SLICC). Attribution of neuorpsychiatric events at diagnosis of systemic lupus erythematosus. Arthritis & Rheumatism 2005;52 (9 suppl) S727. 
29. Bobba R, Su J, Corey P, Shariati Z, Gladman D, Urowitz M, Fortin PR. The influence of treatment of systemic lupus erythematosus (sle) with antimalarials or azatioprine on the risk of thrombosis. Arthritis & Rheumatism 2005;52 (9 suppl) S727. 
 
28. Tisseverasinghe A, Bobba R, Su J, Corey P, Urowitz M, Gladman D, Fortin PR. Elevated serum total cholesterol values are associated with poor renal outcome in systemic lupus erythematosus. Arthritis & Rheumatism 2005;52 (9 suppl) S465. 
 
26. Bernatsky S, Boivin J-F, Joseph L, Rajan R, St. Pierre Y, Ramsey-Goldman R, Clarke AE, Systemic Lupus International Collaborating Clinics (SLICC), Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS). Mortality in systemic lupus erythematosus: Risk according to cause, age, sex and lupus duration. Arthritis & Rheumatism 2005;52 (9 suppl) S726. 
 
25. Bernatsky S, Boivin J-F, Joseph L, Rajan R, St. Pierre Y, Ramsey-Goldman R, Clarke AE, Systemic Lupus International Collaborating Clinics (SLICC), Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS). The Influence of Geographical and Racial/ethnic Factors on Mortality Risk In Systemic Lupus Erythematosus. Arthritis & Rheumatism 2005;52 (9 suppl) S185. 
 
24. Bernatsky S, Boivin J-F, Joseph L, Rajan R, St. Pierre Y, Ramsey-Goldman R, Clarke AE, Systemic Lupus International Collaborating Clinics (SLICC), Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS). Trends in relative mortality rates for systemic lupus erythematosus over calendar time. Arthritis & Rheumatism 2005;52 (9 suppl) S185. 
 
23. Peschken CA, Katz SJ. Lupus and Ethnic Minorities: Disease Outcomes in the Setting of a Universal Healthcare System. 69th Annual Scientific Meeting Of The American- College-Of-Rheumatology/40th Annual Scientific Meeting Of The Association-Of- Rheumatology-Health-Professionals, Nov 12-17, 2005 Arthritis And Rheumatism 52 (9): 420, Suppl. S Sep 2005 
 
2004 
 
2003 
 
21. Bernatsky S, Ramsey-Goldman R, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Urowitz M, Gladman D, Fortin PR, Gordon C, Bae SC, Sibley J, Edworthy S, Barr SG, Isenberg D, Rahman A, El-Gabalawy H, Senecal JL, Zummer M, Steinsson K, Hanly J, Pope J, Nived O, Clarke A. Cancer in Systemic Lupus Erythematosus (SLE): An International Multi-Centre Cohort Study. Arthritis and Rheumatism 2003;48(9 suppl):S696. 
 
2002 
 
2001 
 
17. Chang ER, Fortin PR, Ferland D, Abrahamowicz M. The effect of organ system items on the responsiveness of SLAM-R and SLEDAI to changes in disease activity relevant to physicians and patients. Arthritis & Rheumatism 2000;43[9 suppl]:S148. (Note: abstracts 4 and 5 were presented as one abstract at the Canadian Rheumatology Association conference, Mont-Tremblant, February 2001, and at the Sixth International Lupus Conference, Barcelona, March 2001) 
 
16. Chang E, Abrahamowicz M, Ferland D, Fortin PR. Overall and system-specific responsiveness of SLAM-R and SLEDAI to changes in disease activity relevant to physicians and patients. Journal of Rheumatology 2001;28(6):12. 
 
15. Chang E, Abrahamowicz M, Ferland D, Fortin PR. Overall and system-specific responsiveness of SLAM-R and SLEDAI to changes in disease activity relevant to physicians and patients. Lupus 2001;10(suppl);abstract #315, S109. 
14. Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M, CaNIOS. Study of methotrexate in lupus erythematosus (SMILE): Significant decreased disease activity and steroid sparing effect in patients without damage. Arthritis and Rheumatism 2001;44(9 suppl):S2004. 
 
13. Chang ER, Abrahamowicz M, Ferland D, Fortin PR. Subjective items contribute, independently of objective items, to the responsiveness of SLAM-R to patient- and physician-reported changes in SLE disease activity. Arthritis and Rheumatism 2001;44(9 suppl):S1160. 
 
10. Chang ER, Abrahamowicz M, Ferland D, Fortin PR. Subjective items contribute, independently of objective items, to the responsiveness of SLAM-R to patient- and physician-reported changes in SLE disease activity. Arthritis & Rheumatism 2001;44[9 suppl], S246. 2001. 
 
2000 
 
9. Dobkin P, Clarke A, DaCosta D, & LEAP Group. Supportive-expressive group psychotherapy for women with SLE: A Pan-Canadian randomized clinical trial. Journal of Psychosomatic Research 2000;48:241. 
 
8. Abrahamowicz M, Chang ER, Ferland D, Fortin PR. Responsiveness of SLAM-R and SLEDAI to changes in SLE activity relevant to physicians and patients. Arthritis & Rheumatism 2000;43[9 suppl]:S148. 
 
7. Clarke A, Dobkin P, Da Costa D, St. Pierre Y, Fortin PR, Edworthy S, Barr S, Ensworth S, Esdaile J, Beaulieu A, Senécal JL, Rich E, Choquette D, Goulet JR, Smith D, Cividino A, Zummer M, Gladman D. A randomized multi-site controlled trial of group psychotherapy for SLE. Arthritis & Rheumatism 2000;43(9 suppl):S149. 
 
1999 
 
6. Dobkin PL, Da Costa D, Dritsa M, Fortin PR, Senécal JL, Goulet JR et al. Quality of life in SLE during active and inactive disease states: Differential contributors to mental and physical health. American Psychosomatic Society. Vancouver March 1,1999.  
 
5. For PR, Abrahamowicz M, Ferland D. Lupus disease activity measures are responsive to change in the study of methotrexate in lupus erythematosus (SMILE). Arthritis & Rheumatism 1999;42[9 suppl], S99. 
 
1998 
 
4. Ferland D, Clarke AE, Bélisle P, Joseph L, Fortin PR. Later lupus flares over 4 years as predicted by activity and damage. Lupus 1998;7(Suppl.):67. 
 
3 Da Costa D, Pinard L, Dobkin PL, Clarke AE, Fortin PR, Danoff DS, Esdaile JM. A prospective study on the role of stress in functional disability among women with SLE. Lupus 1998;7(Suppl.):51. 
 
2. Da Costa D, Clarke AE, Dobkin PL, Senécal JL, Goulet JR, Choquette D, Grodzicky T, Fortin PR, Danoff DS, Esdaile JM. Social support and health status influence satisfaction with medical care among patients with systemic lupus erythematosus. Psychosomatic Medicine 1998;60:130. 
 
1997 
 
1. Dobkin PL, Clarke AE, Fortin PR, Esdaile JM, Danoff DS. Reducing distress in systemic lupus erythematosus patients with group psychotherapy. Psychosomatic Medicine 1997;59:77-108 (p.84-85)